NanoPhoria Secures $17.5M to Propel Inhalable Cardiovascular Innovations

NanoPhoria, a preclinical stage biotech company at the forefront of developing inhalable cardiovascular therapies, is excited to announce its successful funding round, having raised $17,500,000 to further its groundbreaking research and clinical development initiatives.

This substantial infusion of capital underscores the strong investor confidence in NanoPhoria’s innovative approach to treating heart conditions and its unique proposition in the biotech arena.

At the core of NanoPhoria’s mission is the development of a proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs via non-viral nano-delivery systems.

Utilizing an inorganic calcium-phosphate nanoparticle, the company has engineered a versatile and biomimetic nano-carrier capable of being loaded or surface decorated with biologics, providing the flexibility to design formulations for inhalation as well as other administration routes.

The funding will specifically bolster the advancement of the company’s lead product, NP-MP1, an inhalable nano-in-micro formulation that delivers a first-in-class calcium channel modulator peptide.

This novel therapy is engineered for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome that impacts millions globally.

The capital raise is expected to accelerate preclinical studies, refine the delivery mechanisms of the nano-carrier platform, and lay the groundwork for subsequent regulatory interactions and eventual clinical trials.

With this milestone, NanoPhoria is poised to make significant strides toward redefining cardiovascular treatment strategies by offering a non-invasive, targeted therapeutic option that could transform patient outcomes.

The company remains committed to pioneering innovative healthcare solutions, and the new funding marks a crucial step forward in its journey to bring this potentially life-changing treatment to market.